20 december 2021: U zou de natuurapotheek kunnen raadplegen hoe en welke Chinese kruiden te gebruiken zijn bij uw vorm van kanker of ziekte.

Wij hebben ook wel het adres van de producent in China van de Sqenqi Fuzheng injecties waar u het via een arts of apotheker kunt bestellen, maar lijkt ons beter dat u dit toch doet via een goed gekwalificeerd arts.
Via dit bedrijf kunt u Kanglaite bestellen via internet: https://www.chinesemedicine.store/kanglaite-injection maar hebt u een arts nodig die dat voor u bestelt.

Het patent voor Kanglaite berust bij deze producent Kanglaite Patent, US

18 november 2021: Bron: 2011 Nov;36(22):3207-9

Opnieuw bewijst een injectie met Kanglaite - Shenqi Fuzheng zijn waarde bij kankerpatiënten. In dit geval bij kankerpatiënten met Acute vorm van leukemie. Kangai-injectie plus FLAG-regime ( fludarabine (Flud), cytosine arabinoside (Ara-C), and granulocyte colony-stimulating factor (G-CSF) (FLAG) ) kan de remissiesnelheid verhogen, de periode van beenmergsuppressie verkorten, de incidentie en mate van infectie aanzienlijk verminderen, en een belangrijke rol spelen bij verminderde efficiëntie bij patiënten met een recidief of progressie van Acute Leukemie. 

Uit het abstract vertaald:

  • Het remissiepercentage van de behandeling en het totale effectieve percentage van de behandelingsgroep waren 57,1% (16/28) en 71,4% (21/28) versus de controlegroep was 52,3% (11/21) en 61,9% (13/21), er waren geen significante verschillen tussen de twee groepen.
  • Duur van neutrofielen minder dan 0,5 x 10(9)/L in behandelingsgroep was (14 +/- 6) dag, in de controlegroep was dat (23 +/- 3) dag,
  • Duur van bloedplaatjes minder dan 25 x 10(9)/ L in behandelingsgroep was (17 +/- 6) dag, in de controlegroep was dat (31 +/- 2) dag,
  • behandelingsgroep van III-IV infectiegraad was 6,9% (1/28) en controlegroep was 23,8% ( 5/21) tussen de twee groepen waren significant verschillend (P <0,05).
  • behandelingsgroep van III-IV graad van gastro-intestinaal; toxiciteit was 10,7% (3/28) en de controlegroep was 28,5% (6/21).
Het abstract van deze studie: 

. 2011 Nov;36(22):3207-9.

[Clinical study of kangai injection plus FLAG regimen for refractory/relapsed acute leukemia]

[Article in Chinese]
  • PMID: 22375409


Objective: To assess the efficacy and toxicity of the kangai injection combination of fludarabine (Flud), cytosine arabinoside (Ara-C), and granulocyte colony-stimulating factor (G-CSF) (FLAG) in refractory/relapsed acute leukemia (AL) patients.

Method: From 2004 to 2010 in our hospital, the 49 cases of refractory/relapsed acute luekemia were randomly divided into treatment group (28 cases) and control group (21 cases). The control group were treated by kangai injection plus FLAG regimen, and the control group were treated by FLAG regimen.

Result: The remission rate of treatment and total effective rate treatment group were 57.1% (16/28) and 71.4% (21/28), the control group were 52.3% (11/21) and 61.9% (13/21), there were no significant differences in the two groups. Duration of neutrophils less than 0.5 x 10(9)/L in treatment group was (14 +/- 6) day, control group was (23 +/- 3) day, Duration of platelet less than 25 x 10(9)/L in treatment group was (17 +/- 6) day, control group was (31 +/- 2) day, treatment group of III-IV degree of infection was 6.9% (1/28) and control group was 23.8% (5/21) between the two groups were significantly different (P < 0.05). treatment group of III- IV degree of gastrointestinal; toxicity was 10.7% (3/28) and control group was 28. 5% (6/ 21).

Conclusion: Kangai injection plus FLAG regimen could increase the remission rate, shorten the period of bone marrow suppression, significantly reduced the incidence and degree of infection, play a important role in attenuated efficiency.

Maar deze reviewstudie geeft nog veel meer waardevolle informatie: 

Clinical Application of Chinese Herbal Injection for Cancer Care: Evidence-Mapping of the Systematic Reviews, Meta-analyses, and Randomized Controlled Trials

Ming Yang, 1 , † Si-jia Zhu, 1 , † Chen Shen, 1 Rui Zhai, 2 Duo-duo Li,corresponding author 2 Min Fang, 1 Jing-nan Xu, 3 , 4 Ye-na Gan, 2 Lu Yang, 3 , 4 Zhi-ying Ren, 5 , 6 Ruo-xiang Zheng, 1 Nicola Robinson, 1 , 7 and Jian-ping Liu 1 , 8 ,*


Background and objective: Cancer is a life-threatening disease worldwide and current standard therapy cannot fulfill all clinical needs. Chinese herbal injections have been widely used for cancer in Chinese and Western hospitals in China. This study aimed to apply evidence mapping in order to provide an overview of the clinical application of Chinese herbal injections in cancer care based on randomized controlled trials, systematic reviews, and meta-analyses.

Methods and results: Seven databases were systematically searched for eligible randomized controlled trials, systematic reviews, and meta-analyses for ten Chinese herbal injections used in cancer treatment and covered in the Chinese national essential health insurance program. Excel 2016 and RStudio were used to integrate and process the data.

In total 366 randomized controlled trials and 48 systematic reviews and meta-analyses were included in the evidence mapping of herbal medicines including; Compound Kushen, Shenqi Fuzheng, Aidi, Kangai, Kanglaite, Xiaoaiping, Cinobufacin, Brucea javanica oil emulsion, Polyporus polysaccharide injection, and Astragalus polysaccharide for injection. Health insurance restricts the scope of clinical application for these herbal injections. The numbers of studies published increased, especially around 2013–2015. The most studied cancer types were lung cancer (118, 32.2%), colorectal cancer (39, 10.7%), and gastric cancer (39, 10.7%), and the most used injections were Compound Kushen (78, 21.3%), Shenqi Fuzheng (76, 20.8%), and Aidi (63, 17.2%). The most consistently reported benefits were observed for Compound Kushen, Shenqi Fuzheng, Aidi, and Kangai for tumor response, quality of life, myelosuppression, and enhancing immunity.

Conclusion:The current evidence mapping provides an overview of the outcomes and effects of Chinese herbal injections used in cancer care, and offers information on their clinical application which warrants further evidence-based research in order to inform clinical and policy decision-making.

Similar articles

Cited by 2 articles


  • General Office of the National Health Commission, Office of the National Administration of Traditional Chinese Medicine (2019). Notice on Printing and Distributing the First Batch of National Key Monitoring Rational Drug Use List (Chemical Drugs and Biological Products). Available at: http://www.nhc.gov.cn/yzygj/s7659/201907/d356ce8a4ba1461ca66c544724dffc5e.shtml (Accessed Feb 2, 2021)
  • Greenlee H., DuPont-Reyes M. J., Balneaves L. G., Carlson L. E., Cohen M. R., Deng G., et al. (2017). Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies during and after Breast Cancer TreatmentCA: a Cancer J. clinicians 67 (3), 194–232. 10.3322/caac.21397 [PMC free article] [PubMed] [CrossRef[]
  • Higgins J. P. T., Altman D. G., Gotzsche P. C., Jüni P., Moher D., Oxman A. D., et al. (2011). The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised TrialsBMJ 343, d5928. 10.1136/bmj.d5928 [PMC free article] [PubMed] [CrossRef[]
  • Horneber M., Bueschel G., Dennert G., Less D., Ritter E., Zwahlen M. (2012). How Many Cancer Patients Use Complementary and Alternative MedicineIntegr. Cancer Ther. 11 (3), 187–203. 10.1177/1534735411423920 [PubMed] [CrossRef[]
  • Kluetz P. G., Chingos D. T., Basch E. M., Mitchell S. A. (2016). Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Am. Soc. Clin. Oncol. Educ. book Am. Soc. Clin. Oncol. Annu. Meet. 36, 67–73. 10.1200/edbk_159514 [PubMed] [CrossRef[]
  • Li H., Wang S., Yue Z., Ren X., Xia J. (2018). Traditional Chinese Herbal Injection: Current Status and Future PerspectivesFitoterapia 129, 249–256. 10.1016/j.fitote.2018.07.009 [PubMed] [CrossRef[]
  • Miake-Lye I. M., Hempel S., Shanman R., Shekelle P. G. (2016). What Is an Evidence Map? A Systematic Review of Published Evidence Maps and Their Definitions, Methods, and ProductsSyst. Rev. 5, 28. 10.1186/s13643-016-0204-x [PMC free article] [PubMed] [CrossRef[]
  • Miake-Lye I. M., Mak S., Lee J., Luger T., Taylor S. L., Shanman R., et al. (2019). Massage for Pain: An Evidence MapJ. Altern. Complement. Med. (New York, NY: ) 25 (5), 475–502. 10.1089/acm.2018.0282 [PMC free article] [PubMed] [CrossRef[]
  • National Health Commission (2018). Notice on the Management of Clinical Application of Adjuvant Drugs: National Health Commission of the People's Republic of China. Available at: http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=bc0259007f1a4cf38cb5d0352470e33e (Accessed Feb 2, 2021).
  • National Health Insurance Agency (2019). Notice of the Ministry of Human Resources and Social Security of the State Medical Insurance Bureau on Printing and Distributing the Drug Catalogue of National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance. Available at: http://www.nhsa.gov.cn/art/2019/8/20/art_37_1666.html (Accessed Feb 2, 2021).
  • Rui Zheng C. Z., Chen S., Zhang X., Zhang H. (2018). Strategy and Path of Precision and Evidence-Based Medicine Promoting the Rational and Legal Application of Traditional Chinese Medicine InjectionWorld Sci. Technology/Modernization Traditional Chin. Med. Materia Med. 20 (10), 1713–1717. 10.11842/wst.2018.10.001 [CrossRef[]
  • Shea B. J., Reeves B. C., Wells G., Thuku M., Hamel C., Moran J., et al. (2017). AMSTAR 2: a Critical Appraisal Tool for Systematic Reviews that Include Randomised or Non-randomised Studies of Healthcare Interventions, or BothBmj 358, j4008. 10.1136/bmj.j4008 [PMC free article] [PubMed] [CrossRef[]
  • Solloway M. R., Taylor S. L., Shekelle P. G., Miake-Lye I. M., Beroes J. M., Shanman R. M., et al. (2016). An Evidence Map of the Effect of Tai Chi on Health OutcomesSyst. Rev. 5 (1), 126. 10.1186/s13643-016-0300-y [PMC free article] [PubMed] [CrossRef[]
  • Terret C., Albrand G., Moncenix G., Droz J. P. (2011). Karnofsky Performance Scale (KPS) or Physical Performance Test (PPT)? That Is the QuestionCrit. Rev. oncology/hematology 77.(2), 142–147. 10.1016/j.critrevonc.2010.01.015 [PubMed] [CrossRef[]
  • The International Agency for Research on Cancer (IARC) (2020). Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020. Available at: https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/ (Accessed Feb 2, 2021)
  • Wang Z., Qi F., Cui Y., Zhao L., Sun X., Tang W., et al. (2018). An Update on Chinese Herbal Medicines as Adjuvant Treatment of Anticancer TherapeuticsBst 12 (3), 220–239. 10.5582/bst.2018.01144 [PubMed] [CrossRef[]
  • Wei H., Xiao Y., Tong Y., Chen Y., Luo X., Wang Y., et al. (2019). Therapeutic Effect of Angelica and its Compound Formulas for Hypertension and the Complications: Evidence MappingPhytomedicine 59, 152767. 10.1016/j.phymed.2018.11.027 [PubMed] [CrossRef[]
  • Xu Y., Mao J. J., Sun L., Yang L., Li J., Hao Y., et al. (2017). Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients with Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort StudyJ. Natl. Cancer Inst. Monogr. 2017 (52), lgx015. 10.1093/jncimonographs/lgx015 [PMC free article] [PubMed] [CrossRef[]
  • Yeung K. S., Gubili J., Mao J. J. (2018). Herb-Drug Interactions in Cancer CareOncology (Williston Park, NY) 32 (10), 516-20. 10.1002/ptr.6033 [PubMed] [CrossRef[]
  • Zhang D., Ni M., Wu J., Liu S., Meng Z., Tian J., et al. (2018). The Optimal Chinese Herbal Injections for Use with Radiotherapy to Treat Esophageal Cancer: A Systematic Review and Bayesian Network Meta-AnalysisFront. Pharmacol. 9, 1470. 10.3389/fphar.2018.01470 [PMC free article] [PubMed] [CrossRef[]
  • Zheng C.-l., Hou K.-z., Wang A.-q., Fang W.-x., Yu S.-t., Liang J.-e., et al. (2020). Kang-ai Injection (康艾注射液) Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 PathwayChin. J. Integr. Med. 10.1007/s11655-020-3265-6 [PubMed] [CrossRef[]
  • Zhu G., Zhang B., Jiang F., Zhao L., Liu F. (2019). ShenQi FuZheng Injection Ameliorates Fatigue-like Behavior in Mouse Models of Cancer-Related FatigueBiomed. Pharmacother. 111, 1376–1382. 10.1016/j.biopha.2019.01.042 [PubMed] [CrossRef[]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

Plaats een reactie ...

Reageer op "Kangai-injectie plus FLAG chemokuur verbetert kans op complete remissie, verkort de periode van beenmergsuppressie en vermindert aantal en ernst van infecties"

Gerelateerde artikelen

Gerelateerde artikelen

Shenqi Fuzheng injectie voor >> Kanglaite: wat is het en wat >> Fuzheng Yiliu-afkooksel (Kanglaite) >> Kangai-injectie plus FLAG >> Shenqi Fuzheng Injectie samen >> Kanglaite door FDA goedgekeurd >> Kanglaite injecties geven >> Shenqi Fuzheng injectie, mix >> Fuzheng Yiliu Granule (TCM) >> Traditionele Chinese kruiden >>